Notice of Interim Results

Ergomed

20/08/2020 07:00

RNS Number : 6329W

Ergomed plc

20 August 2020

 

 

PRESS RELEASE

 

Notice of Interim Results

 

 

Guildford, UK - 20 August 2020: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialized services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2020 on 22 September 2020.

 

Miroslav Reljanović, Executive Chairman and Richard Barfield, Chief Financial Officer will host a virtual presentation and conference call for analysts at 9am BST on the day of the results.

 

ENDS

 

Enquiries:

 

Ergomed plc
Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Sue Stuart
ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognized specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 
  END

 

 
NORBLGDIRUBDGGC